Travis Whitfill is 2014 graduate of YSPH and is a serial biotech entrepreneur and investor. His background began in biochemistry and molecular biology at the MD Anderson Cancer Center and Duke University before starting at YSPH in 2012. He is currently a Partner at Bios Partners, which is a life science-focused venture capital firm in Texas with over $300 million assets under management. He sits on the board of five portfolio companies, including IN8bio (NASDAQ: INAB), a public company, and Azitra Inc., SIRPant Inc., Immusoft Corporation, and 410 Medical, Inc. He is the co-founder of several startup companies, including Azitra Inc. which is a mid-clinical stage medical dermatology company. His background in entrepreneurship and business and was acknowledged as Forbes’ 30 Under 30 in healthcare in 2018. He’s also the Senior Analyst at Bios Research, which brings experience in public markets, and drug development to support venture capital investments. Mr. Whitfill is also an academic researcher and also holds a faculty appointment at Yale in the Departments of Emergency Medicine and Pediatrics as an Associate Research Scientist. Related to this work, he is sits on the board of several international research networks, including the International Pediatric Simulation Society (IPSS) and the International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) and is the Treasurer for both organizations. Mr. Whitfill has been the principal investigator (PI) or co-PI of over $18 million in federal grants/contracts, holds nearly a dozen patents, and has co-authored over 50 publications and book chapters. Mr. Whitfill received degrees from Yale School of Public Health (MPH) and Dallas Baptist University (BS) and is working on a PhD in healthy policy from University College London.